TPP allies with Sprint Bioscience to develop cancer drugs

11/1/2012 | Pharmaceutical Business Review Online

Sprint Bioscience and TPP Global Development agreed to collaborate in the development of small molecule choline kinase inhibitors for treatment of cancer. "Choline kinase is an exciting metabolic target and fits well within the rest of TPP's cancer metabolism portfolio," TPP CEO Tom Brown said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL